1. In Vivo

Does The SPAC Have A Future In Biopharma?

Special Purpose Acquisition Companies Can Speed Up Going Public, But There Are Risks

 
• By Chloe Kent

Special purpose acquisition companies can bring biopharma firms to market faster than a traditional initial public offering, but frequent failures and increased scrutiny from the US Securities and Exchange Commission mean their heyday in the life sciences space is arguably over.    

Speed lights
• Source: Shutterstock

For biopharmaceutical companies looking to go public, merging with a special purpose acquisition company can be an appealing alternative to the ‘traditional’ initial public offering process. Rather than teaming up with an underwriter to start selling its shares on a public exchange for the first time, a firm can merge with a publicly listed shell company – the SPAC. But following the SPAC boom of 2020 and 2021, when dozens of SPACs launched and began their search for a partner, the bubble seems to have finally burst.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

Laying The Foundation And Overcoming Prerequisites To Establish AI Within Health Care

 
• By Mike King

As the health care industry undergoes a digital transformation, the integration of AI into Quality and Regulatory Management Systems is proving essential. The challenges for successful AI deployment emphasize the need for robust digital infrastructure, data literacy programs and privacy measures to enhance patient safety and commercial performance.

Aurion Biotech’s Ophthalmic Cell Therapy For The Masses

 
• By David Wild

Aurion Biotech is developing a cell therapy for corneal diseases that is cheap enough to produce and can be scaled that it should reach the masses in a way that other cell therapies cannot.

Neurodegenerative Disease Investment: Shifting Paradigms Beyond Amyloid And Tau

 
• By David Wild

Companies are exploring new mechanisms of action beyond traditional amyloid and tau and both investors and big pharma are willing to make deals when the science is compelling, panelists at Biotech Showcase said.

Licensing For Innovation: A Decade Of Pharma Product Deals

 
• By Edwin Elmhirst

Licensing deals have been growing in popularity over outright acquisitions in the pharmaceutical industry over the past decade. Licensing deals have doubled in number from 2015 to 2024, while M&A activity has decreased post-COVID. We consider the advantages of licensing deals and review notable licensing deals from the past 10 years with the potential to deliver high value relative to their initial investment.

More from In Vivo

Rising Leaders 2025: Partnerships Propel Crystal Qin’s LaNova To Record-Breaking Merck Deal

 
• By Brian Yang

Crystal Qin has led LaNova Medicines’ swift rise in the biotech world through strategic partnerships and innovative R&D, highlighted by a record deal with big pharma.

Rising Leaders 2025: Amir Hefni Puts Optimism Into Action At Resolution Therapeutics

 
• By Jo Shorthouse

In Vivo Rising Leader Amir Hefni, CEO of Resolution Therapeutics, discusses the company's advancements in macrophage cell therapies for inflammatory and fibrotic diseases, and his transition from big pharma to biotech leadership.

In Vivo’s 2025 Rising Leaders

 
• By Jo Shorthouse

The sixth annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.